Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 10Thoracic 3Sarcoma 3Breast 3Tumor-Agnostic 2Head & Neck 2Genitourinary 2Plasma cell 1Lymphoid 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Alveolar Soft Part 1Neoplasm Metastasis 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Carboplatin 1174Cisplatin 891Pemetrexed 847pembrolizumab 626Paclitaxel 609Docetaxel 539Gemcitabine 428Radiotherapy 393Erlotinib Hydrochloride 381Nivolumab 344Bevacizumab 337Etoposide 297durvalumab 264Drug Therapy 260osimertinib 237atezolizumab 225Radiosurgery 196Gefitinib 186Vinorelbine 149Magnetic Resonance Spectroscopy 132Ipilimumab 129130-nm albumin-bound paclitaxel 125Cetuximab 113Blood Specimen Collection 106anlotinib 105tislelizumab 103Topotecan 103Specimen Handling 102Surgical Procedures, Operative 101Cyclophosphamide 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
futibatinib × Thoracic × Clear all
NCT05827614 2026-01-23

POTENTIATE

Boundless Bio, Inc.

Phase 1 Active not recruiting
85 enrolled
BreastHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Leiomyosarcoma, Histiocytoma, Malignant Fibrous, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04999761 2024-09-25

AB122 Platform Study

Taiho Pharmaceutical Co., Ltd.

Phase 1 Recruiting
917 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

NCT04965818 2024-09-19

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

Taiho Oncology, Inc.

Phase 1 Terminated
38 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡